今年的冬季对于北半球的国家来说都是不小的考验,少见的极寒对公众健康势必带来较大影响,特别是流感或季节性感冒的发病率很可能较大幅度攀升。如何合理预防以及发病后如何正确用药都是非常重要的。1999年首先在瑞士上市的奥司他韦(达菲)是一种强效、高选择性的流感病毒神经氨酸酶抑制剂,可竞争性地与流感病毒神经氨酸酶的活动位点结合,通过干扰病毒从被感染的宿主细胞中释放,从而 This year’s winter is a test for countries in the northern hemisphere. The rare cold is bound to have a great impact on public health. In particular, the incidence of influenza or seasonal influenza is likely to rise substantially. How to properly prevent and how to correct medication after the onset are very important. The oseltamivir (Tamiflu), first marketed in Switzerland in 1999, is a potent and highly selective influenza virus neuraminidase inhibitor that binds competitively to the active site of influenza virus neuraminidase , By interfering with the release of the virus from the infected host cell